All In Biotech

Drug Trial Radar · NCT06846268

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Phase II Trial of Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Apr 14, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
National University Hospital, SingaporeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Adagene Inc
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.

Conditions

  • Locally Advanced Colorectal Cancer

Interventions

  • ADG126Drug

    Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W).

  • PembrolizumabDrug

    Administered via intravenous infusion on Day 1 and Day 22.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Major Pathologic Response (MPR)Time frame: Up to 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National University Hospital

    Singapore, Singapore · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.